Price Don’t Lie: How Analysts Feel About Organovo Holdings Inc After Today’s Big Increase?

Price Don't Lie: How Analysts Feel About Organovo Holdings Inc After Today's Big Increase?

The stock of Organovo Holdings Inc (NASDAQ:ONVO) is a huge mover today! About 423,488 shares traded hands. Organovo Holdings Inc (NASDAQ:ONVO) has risen 11.39% since April 26, 2016 and is uptrending. It has outperformed by 6.13% the S&P500.
The move comes after 7 months positive chart setup for the $306.82M company. It was reported on Nov, 29 by Barchart.com. We have $3.27 PT which if reached, will make NASDAQ:ONVO worth $15.34M more.

Analysts await Organovo Holdings Inc (NASDAQ:ONVO) to report earnings on February, 13. They expect $-0.10 earnings per share, up 9.09% or $0.01 from last year’s $-0.11 per share. After $-0.10 actual earnings per share reported by Organovo Holdings Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

According to Zacks Investment Research, “Organovo Holdings, Inc. is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications. Its NovoGen 3D printing technology is a platform that works across various tissue and cell types. Organovo Holdings, Inc. is based in San Diego, California.”

Insitutional Activity: The institutional sentiment increased to 1.58 in 2016 Q2. Its up 0.58, from 1 in 2016Q1. The ratio increased, as 3 funds sold all Organovo Holdings Inc shares owned while 35 reduced positions. 11 funds bought stakes while 27 increased positions. They now own 17.18 million shares or 1.14% less from 17.37 million shares in 2016Q1.
Hartford Fin Mgmt reported 300 shares or 0% of all its holdings. Us Bancorporation De accumulated 5,536 shares or 0% of the stock. Lehman Financial has 0.24% invested in the company for 131,400 shares. Blackrock Institutional Tru Com Na reported 2.10M shares or 0% of all its holdings. The Nebraska-based Cwm Limited Company has invested 0% in Organovo Holdings Inc (NASDAQ:ONVO). Lpl Financial Ltd Liability Com accumulated 0% or 106,520 shares. Ameriprise Fincl Inc last reported 0% of its portfolio in the stock. Deltec Asset Ltd has invested 0.01% of its portfolio in Organovo Holdings Inc (NASDAQ:ONVO). Intl Grp accumulated 0% or 49,563 shares. Cambridge Invest Advsr accumulated 90,524 shares or 0.01% of the stock. Messner & Smith Theme Value Inv Mngmt Limited Ca, a California-based fund reported 41,230 shares. Legal General Grp Pcl owns 12,417 shares or 0% of their US portfolio. Tradewinds Mngmt Ltd Limited Liability Company, a Washington-based fund reported 30 shares. Morgan Stanley holds 0% of its portfolio in Organovo Holdings Inc (NASDAQ:ONVO) for 296,099 shares. Next Gp Inc holds 0.01% of its portfolio in Organovo Holdings Inc (NASDAQ:ONVO) for 12,400 shares.

Insider Transactions: Since August 5, 2016, the stock had 0 insider buys, and 1 insider sale for $91,000 net activity. David Eric sold $91,000 worth of Organovo Holdings Inc (NASDAQ:ONVO) on Friday, August 5.

More notable recent Organovo Holdings Inc (NASDAQ:ONVO) news were published by: Fool.com which released: “How Much Is Organovo Holdings, Inc. Really Worth?” on November 10, 2016, also Fool.com with their article: “3 Things to Watch in Organovo Holdings, Inc. Q2 Results” published on October 27, 2016, Fool.com published: “Why Organovo Holdings Inc. Is Up 27% This Year” on June 30, 2016. More interesting news about Organovo Holdings Inc (NASDAQ:ONVO) were released by: Fool.com and their article: “3 Reasons Why Organovo Holdings Inc. Should Rebound Big” published on November 04, 2016 as well as Fool.com‘s news article titled: “Better Buy: Organovo Holdings, Inc. vs. United Therapeutics Corporation” with publication date: October 14, 2016.

ONVO Company Profile

Organovo Holdings, Inc., incorporated on January 27, 2012, is an early commercial-stage firm focused on developing and commercializing functional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The Firm focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D that mimic native human tissue composition, architecture and function.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment